Navigation Links
Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide
Date:11/9/2009

d syncope were observed in clinical trials. Use INTUNIV with caution in treating patients who have experienced hypotension, bradycardia, heart block, or syncope, or who may have a condition that predisposes them to syncope; are treated concomitantly with antihypertensives or other drugs that can reduce blood pressure or heart rate or increase the risk of syncope. Heart rate and blood pressure should be measured prior to initiation of therapy, following dose increases, and periodically while on therapy. Patients should be advised to avoid becoming dehydrated or overheated.

Sedation and somnolence were commonly observed in clinical trials. The potential for additive sedative effects with CNS depressant drugs should be considered. Patients should be cautioned against operating heavy equipment or driving until they know how they respond to INTUNIV. Avoid use with alcohol.

Common adverse reactions in patients taking INTUNIV that may be dose related over the range of 1 to 4 mg/day include somnolence, sedation, abdominal pain, dizziness, hypotension/decreased blood pressure, dry mouth, and constipation.

About ADHD

ADHD is one of the most common psychiatric disorders in children and adolescents. Worldwide prevalence of ADHD is estimated at 5.3 percent (with large variability), according to a comprehensive systematic review of this topic published in 2007 in the American Journal of Psychiatry. In the United States, approximately 7.8 percent of all school-aged children, or about 4.4 million children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the Centers for Disease Control and Prevention (CDC).

ADHD is a psychiatric behavioral disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. The specific etiolog
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
2. New Data Show Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Demonstrated Significant ADHD Symptom Reduction when Assessed Using the Oppositional Subscale of the Conners ADHD Rating Scale
3. Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections
4. Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
5. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
6. Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing
7. New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
8. New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation
9. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
10. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
11. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... FRANKLIN, Mass. , Aug. 27, 2015 /PRNewswire/ ... in the KSSTA Knee Journal, compared the Arthrosurface ... "inlay" Arthroplasty design, versus an "onlay" design implant ... showed similar improvements in function and pain scores, ... showed progression of osteoarthritis (OA). However, 53% of ...
(Date:8/27/2015)... According to a new market research report "Medical Lifting ... ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), End User ... Medical Lifting Sling Market is poised to reach USD 706.0 Million ... of 11.4 % from 2015 to 2020. , ... ables and 65 F igures ...
(Date:8/27/2015)... BIRMINGHAM, Ala. , Aug. 27, 2015 ... Integrated Outpatient Pharmacy Provider (IOPP™) is expanding ... launch of a medication-focused transition of care ... program, named "RxCare Management," provides hospitals with ... improve hospital performance measures that have been ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4Rx Care Management by Proxsys Rx - Transition of Care Technology Helps Prevent Hospital Medication Errors 2
... 2011 Nektar Therapeutics (Nasdaq: NKTR ) ... 2 clinical study of NKTR-102 in patients with metastatic ... Cancer Symposium in San Francisco, California.  NKTR-102 is a ... conjugate technology, and is being developed in multiple tumor ...
... The Board of the European Fine Chemicals ... to ratify the proposal of the US Food and Drug ... the help of EFCG and US industry representatives, to deliver ... (GDUFA). GDUFA requires the FDA to commit to ...
Cached Medicine Technology:Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 2Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 3Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 4Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 5Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 6European Fine Chemicals Group Ratifies FDA's Proposed Generic Drug User Fees Act (GDUFA) 2
(Date:8/28/2015)... ... August 28, 2015 , ... “ Frequentz ” was featured on NewsWatch ... coolest applications on the market for iOS, Android, and Windows. Joe Toohey, the host ... this software allows businesses to track product movement from beginning to end. , Businesses ...
(Date:8/28/2015)... ... August 28, 2015 , ... CARF ... its adolescent residential, counseling, day treatment and intensive family based services. , By ... for quality and its pursuit of excellence. As a nonprofit charity for more ...
(Date:8/28/2015)... ... August 28, 2015 , ... Mendon, IL, home of the Adams County ... people, all for a good cause. In its second year, the “Music With A ... Best Drug Rehabilitation. The “Mission” of “Music With A Mission” is to raise money ...
(Date:8/28/2015)... ... August 28, 2015 , ... Researchers ... comprehensive information on two new duals programs: Rhode Island Integrated Care Initiative, ... Idaho’s partnership to revamp Blue Cross of Idaho’s D-SNP. The database also ...
(Date:8/28/2015)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... in order to ease the stress on the atmosphere, and lessen the number and ... the real cause of global warming and urges them to look into his studies ...
Breaking Medicine News(10 mins):Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2
... Enhanced design now features End-of-Life capability and longer ... LLC, a leading supplier of batteries for implantable ... enhanced Lithium Carbon Monofluoride (Li/CFx) battery technology with ... the market. The technology includes a proprietary new ...
... Remote Magnetic Navigation prominently featured on the HRS 2009 ... STXS ) said today that the Heart Rhythm ... in which its Niobe system is either featured or ... presentations include new efficacy data on the use of ...
... takes shared responsibility to a whole new level. ... saving $2 trillion in healthcare costs over the next ... is within our grasp.Blue Shield of California has long ... We are pleased that these groups are embracing the ...
... emerging pandemic of a new strain of influenza A (H1N1) ... , Researchers from the MRC Centre for Outbreak Analysis and ... World Health Organisation and public health agencies in Mexico, have ... Their key findings are as follows: , , ...
... Drug Information Association (DIA), the premiere neutral, global, multidisciplinary association ... the launch of its new online Career Center--a highly targeted ... ... Horsham, PA, USA (Vocus) May 11, 2009 -- The ...
... on Kidz-Med Thermofocus(R) 5-in-1WESTON, Fla., May 11 American ... revenue results for the first quarter ending March 31, ... with net sales of $263,603 for the first quarter ... for the first quarter of 2008.The sales increase was ...
Cached Medicine News:Health News:EaglePicher Medical Power Announces New Li/CFx Battery Technology 2Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 2Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 3Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 4Health News:Swine flu: Early findings about pandemic potential reported in new study 2Health News:Drug Information Association (DIA) Launches New Online Career Center 2Health News:Drug Information Association (DIA) Launches New Online Career Center 3Health News:American Scientific Resources, Inc. Releases First Quarter Revenues 2
... The BiPAP Pro with Bi-Flex bi-level system, ... that the BiPAP Pro takes to change ... Digital Auto-Trak Sensitivity™ which automatically triggers the ... pressures based on the patients breathing rhythm. ...
... Electrophoresis System (PGGE) is designed to ... density lipoproteins (LDL) and high density ... using nondenaturing pore gradient gel electrophoresis. ... short DNA sequencing runs. Temperature control ...
This control is intended for monitoring cell counts in patient cerebrospinal fluid samples, performed manually using a hemocytometer. Spinalscopics is fortified to target levels with purified chemica...
... Suitable for use with Leica ... bilirubinometers (pediatric) and all automated ... including Aeroset, AU Series, Cobas, ... These controls contain purified bilirubin ...
Medicine Products: